NASDAQ:AUTL - Autolus Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $18.86
  • Forecasted Upside: 147.14 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$7.63
▼ -0.33 (-4.15%)
1 month | 3 months | 12 months
Get New Autolus Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AUTL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AUTL

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$18.86
▲ +147.14% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Autolus Therapeutics in the last 3 months. The average price target is $18.86, with a high forecast of $38.00 and a low forecast of $9.00. The average price target represents a 147.14% upside from the last price of $7.63.

Buy

The current consensus among 8 contributing investment analysts is to buy stock in Autolus Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/24/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/19/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/18/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/18/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/17/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/14/2021Jefferies Financial GroupUpgradeHold ➝ Buy$6.00 ➝ $12.00Low
i
5/6/2021Needham & Company LLCLower Price TargetBuy$26.00 ➝ $21.00Medium
i
3/16/2021Redburn PartnersReiterated RatingBuy ➝ NeutralHigh
i
3/10/2021Redburn PartnersDowngradeBuy ➝ NeutralLow
i
1/29/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$24.00 ➝ $9.00High
i
1/7/2021TruistLower Price Target$30.00 ➝ $15.00N/A
i
1/7/2021HC WainwrightLower Price TargetBuy$19.00 ➝ $13.00N/A
i
Rating by R. Burns at HC Wainwright
1/6/2021MizuhoReiterated RatingBuy$24.00N/A
i
12/28/2020HC WainwrightReiterated RatingBuy$19.00N/A
i
Rating by R. Burns at HC Wainwright
12/8/2020Needham & Company LLCReiterated RatingBuy$26.00High
i
11/25/2020Redburn PartnersInitiated CoverageBuyHigh
i
9/23/2020William BlairReiterated RatingBuyHigh
i
Rating by Matt Phipps at William Blair
9/18/2020Needham & Company LLCReiterated RatingBuy$26.00High
i
Rating by Chad Messer at Needham & Company LLC
8/6/2020MizuhoReiterated RatingBuy$24.00Low
i
Rating by Mara Goldstein at Mizuho
7/31/2020JPMorgan Chase & Co.Initiated CoverageOverweight$25.00Low
i
7/22/2020SunTrust BanksInitiated CoverageBuy$38.00High
i
6/26/2020HC WainwrightReiterated RatingBuy$24.00Low
i
Rating by Debjit Chattopadhyay at HC Wainwright
6/25/2020William BlairReiterated RatingBuyLow
i
Rating by Matt Phipps at William Blair
6/19/2020MizuhoBoost Price TargetBuy$18.00 ➝ $24.00Medium
i
Rating by Mara Goldstein at Mizuho
6/17/2020Jefferies Financial GroupReiterated RatingBuy$27.00Low
i
6/17/2020William BlairReiterated RatingBuyMedium
i
6/2/2020William BlairReiterated RatingBuyHigh
i
6/1/2020Needham & Company LLCInitiated CoverageBuy$26.00High
i
Rating by Chad Messer at Needham & Company LLC
5/29/2020MizuhoReiterated RatingBuy$18.00High
i
Rating by Mara Goldstein at Mizuho
5/8/2020HC WainwrightReiterated RatingBuyHigh
i
Rating by D. Chattopadhyay at HC Wainwright
5/7/2020Needham & Company LLCReiterated RatingBuy$26.00High
i
4/21/2020MizuhoInitiated CoverageBuy$18.00High
i
12/9/2019HC WainwrightReiterated RatingBuy$24.00Low
i
Rating by D. Chattopadhyay at HC Wainwright
11/8/2019HC WainwrightReiterated RatingBuyHigh
i
Rating by D. Chattopadhyay at HC Wainwright
11/7/2019William BlairReiterated RatingBuyHigh
i
Rating by Matt Phipps at William Blair
9/23/2019Needham & Company LLCInitiated CoverageBuy$26.00 ➝ $26.00Low
i
9/12/2019HC WainwrightReiterated RatingBuy$24.00Low
i
Rating by Debjit Chattopadhyay at HC Wainwright
9/3/2019William BlairReiterated RatingBuyLow
i
Rating by Matt Phipps at William Blair
5/17/2019HC WainwrightReiterated RatingBuy ➝ Buy$45.00 ➝ $41.00Low
i
Rating by Debjit Chattopadhyay at HC Wainwright
4/3/2019William BlairReiterated RatingBuyLow
i
2/20/2019HC WainwrightSet Price TargetBuy$45.00Medium
i
Rating by Debjit Chattopadhyay at HC Wainwright
11/29/2018Wells Fargo & CompanyReiterated RatingBuy$38.00 ➝ $50.00Medium
i
11/2/2018HC WainwrightReiterated RatingBuy$45.00High
i
Rating by D. Chattopadhyay at HC Wainwright
10/24/2018HC WainwrightInitiated CoverageBuy ➝ BuyMedium
i
Rating by D. Chattopadhyay at HC Wainwright
7/26/2018The Goldman Sachs GroupInitiated CoverageNeutralLow
i
7/17/2018Wells Fargo & CompanyInitiated CoverageOutperform$38.00High
i
7/17/2018William BlairInitiated CoverageOutperformHigh
i
Rating by M. Phipps at William Blair
7/17/2018Jefferies Financial GroupInitiated CoverageBuy$37.00High
i
(Data available from 6/16/2016 forward)
Autolus Therapeutics logo
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; AUTO3NG for the treatment of hematological cancer; AUTO4 and AUTO5 for T cell lymphoma; AUTO6NG for the treatment of programmed T cell therapies; AUTO6 for the treatment of neuroblastoma; and AUTO7 for the treatment of prostate cancer. Autolus Therapeutics plc was founded in 2014 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $7.63
$7.31
$8.00

50 Day Range

MA: $6.05
$4.78
$7.96

52 Week Range

Now: $7.63
$4.60
$17.19

Volume

2,136,242 shs

Average Volume

1,162,154 shs

Market Capitalization

$538.03 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.7

Frequently Asked Questions

What sell-side analysts currently cover shares of Autolus Therapeutics?

The following Wall Street research analysts have issued research reports on Autolus Therapeutics in the last year: HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Mizuho, Needham & Company LLC, Redburn Partners, SunTrust Banks, Inc., Truist, William Blair, and Zacks Investment Research.
View the latest analyst ratings for AUTL.

What is the current price target for Autolus Therapeutics?

7 Wall Street analysts have set twelve-month price targets for Autolus Therapeutics in the last year. Their average twelve-month price target is $18.86, suggesting a possible upside of 147.1%. SunTrust Banks, Inc. has the highest price target set, predicting AUTL will reach $38.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $9.00 for Autolus Therapeutics in the next year.
View the latest price targets for AUTL.

What is the current consensus analyst rating for Autolus Therapeutics?

Autolus Therapeutics currently has 2 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AUTL will outperform the market and that investors should add to their positions of Autolus Therapeutics.
View the latest ratings for AUTL.

What other companies compete with Autolus Therapeutics?

How do I contact Autolus Therapeutics' investor relations team?

Autolus Therapeutics' physical mailing address is FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ. The company's listed phone number is 44-20-3829-6230 and its investor relations email address is [email protected] The official website for Autolus Therapeutics is www.autolus.com.